{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T15:32:31Z","timestamp":1702740751372},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/wco.0b013e32830f226d","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T11:04:35Z","timestamp":1220439875000},"page":"534-539","source":"Crossref","is-referenced-by-count":8,"title":["Neuropathies in the context of malignancies"],"prefix":"10.1097","volume":"21","author":[{"given":"Anthony","family":"Behin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khe","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Leger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210206","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2004-861535","article-title":"Complications of radiation therapy on the brain and spinal cord","volume":"24","author":"Behin","year":"2004","journal-title":"Semin Neurol"},{"key":"R2-5-20210206","first-page":"778","article-title":"Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis J Neurol Neurosurg P","volume":"79","author":"Viala","year":"2008","journal-title":"sychiatry"},{"key":"R3-5-20210206","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0404.2006.00781.x","article-title":"Vasculitic neuropathy-electrodiagnostic findings and association with malignancies","volume":"115","author":"Zivkovic","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"R4-5-20210206","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.23085","article-title":"Vasculitides associated with malignancies: analysis of sixty patients","volume":"57","author":"Fain","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","article-title":"Management of paraneoplastic neurological syndromes: report of an EFNS Task Force","volume":"13","author":"Vedeler","year":"2006","journal-title":"Eur J Neurol"},{"key":"R6-5-20210206","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R7-5-20210206","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"124","author":"Graus","year":"2001","journal-title":"Brain"},{"key":"R8-5-20210206","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1212\/01.wnl.0000266668.03638.94","article-title":"Ataxic vs painful form of paraneoplastic neuropathy","volume":"68","author":"Oki","year":"2007","journal-title":"Neurology"},{"key":"R9-5-20210206","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/WCO.0b013e3282f1a06e","article-title":"Neurologic complications of chemotherapy agents","volume":"20","author":"Kannarkat","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"R10-5-20210206","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/brain\/awl356","article-title":"Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies","volume":"130","author":"Krarup-Hansen","year":"2007","journal-title":"Brain"},{"key":"R12-5-20210206","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/02841860701355055","article-title":"Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer","volume":"46","author":"Argyriou","year":"2007","journal-title":"Acta Oncol"},{"key":"R13-5-20210206","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage.","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-05-2076","article-title":"Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy","volume":"12","author":"Lecomte","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R15-5-20210206","first-page":"249","article-title":"Management of oxaliplatin-induced peripheral neuropathy","volume":"1","author":"Saif","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"R16-5-20210206","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10637-006-9010-y","article-title":"Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study","volume":"25","author":"von Delius","year":"2007","journal-title":"Invest New Drugs"},{"key":"R17-5-20210206","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","article-title":"Efficacy of oxcarbazepine","volume":"67","author":"Argyriou","year":"2006","journal-title":"Neurology"},{"key":"R18-5-20210206","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","article-title":"Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients","volume":"12","author":"Wang","year":"2007","journal-title":"Oncologist"},{"key":"R19-5-20210206","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1533-0028(11)70214-6","article-title":"Highlights from the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006","volume":"5","author":"Gibson","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","article-title":"Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer","volume":"10","author":"Gamelin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R21-5-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/annonc\/mdl336","article-title":"Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study","volume":"18","author":"Andr\u00e9","year":"2007","journal-title":"Ann Oncol"},{"key":"R22-5-20210206","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000098107","article-title":"FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer","volume":"70","author":"Petrioli","year":"2006","journal-title":"Oncology"},{"key":"R23-5-20210206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer \u2013 a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"key":"R24-5-20210206","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nano-particle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"R25-5-20210206","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1349-7006.2008.00792.x","article-title":"Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile","volume":"99","author":"Hattori","year":"2008","journal-title":"Cancer Sci"},{"key":"R26-5-20210206","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R27-5-20210206","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"R28-5-20210206","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"R29-5-20210206","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"R30-5-20210206","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.11752","article-title":"Bortezomib-induced peripheral neurotoxicity: still far from a painless gain","volume":"92","author":"Cavaletti","year":"2007","journal-title":"Haematologica"},{"key":"R31-5-20210206","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"R32-5-20210206","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"key":"R33-5-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"R34-5-20210206","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1212\/01.WNL.0000092015.03923.19","article-title":"Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale","volume":"61","author":"Cavaletti","year":"2003","journal-title":"Neurology"},{"key":"R35-5-20210206","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdh348","article-title":"Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy","volume":"15","author":"Cavaletti","year":"2004","journal-title":"Ann Oncol"},{"key":"R36-5-20210206","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","article-title":"Multicenter assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity","volume":"11","author":"Cavaletti","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"R37-5-20210206","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ncpneuro0740","article-title":"NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?","volume":"4","author":"Hughes","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"R38-5-20210206","first-page":"44","article-title":"Late side-effects are common after treatment of Hodgkin's disease. Muscular atrophy following radiotherapy is a neglected risk","volume":"95","author":"Johansson","year":"1998","journal-title":"Lakartidningen"},{"key":"R40-5-20210206","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/mus.20623","article-title":"Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease","volume":"34","author":"Rowin","year":"2006","journal-title":"Muscle Nerve"},{"key":"R41-5-20210206","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/brain\/119.5.1429","article-title":"The postirradiation lower motor neuron syndrome neuronopathy or radiculopathy?","volume":"119","author":"Bowen","year":"1996","journal-title":"Brain"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e32830f226d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T23:49:47Z","timestamp":1631749787000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-200810000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32830f226d","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}